Jagsonpal Pharmaceuticals has fixed Friday, September 04, 2026, as the record date to determine member entitlement for the dividend declared for the financial year ended March 31, 2026. This action follows the Board of Directors' recommendation on April 27, 2026, of a dividend of ₹4 per equity share, representing a 200% payout on the face value of ₹2. The distribution is contingent upon final approval by shareholders at the company's 47th Annual General Meeting (AGM).

The AGM is scheduled for Friday, September 18, 2026, at 03:30 p.m. (IST). In compliance with circulars issued by the Ministry of Corporate Affairs and the Securities and Exchange Board of India (SEBI), the meeting will be conducted through Video Conferencing (VC) or Other Audio Visual Means (OAVM). Shareholders holding equity shares on the specified record date will be eligible to receive the dividend if the resolution passes.

Dividend Details

The following table outlines the key parameters of the proposed dividend distribution:

Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Jagsonpal Pharmaceuticals issued this intimation to the BSE Ltd and the National Stock Exchange of India Ltd. The company stated that the dividend, once approved by members at the AGM, will be paid within 30 days from the date of its declaration. Payments will be subject to the deduction of applicable taxes at source.

What the Numbers Show

The proposed dividend represents a significant return to shareholders, with the payout amounting to twice the face value of the equity shares. This high payout ratio suggests strong liquidity or retained earnings position for the firm in FY26. The separation of the record date (September 04) from the AGM date (September 18) provides a clear window for trade settlement, ensuring that investors who acquire shares before the record date are eligible for the distribution, provided the Board's recommendation is ratified by the general body of shareholders.

Jagsonpal Pharmaceuticals Ltd has designated two senior executives as Senior Management Personnel (SMP) effective July 29, 2026, following an internal restructuring. The company informed the Bombay Stock Exchange and the National Stock Exchange of India Ltd that Balmukund Keshav and Sanjay Singhal have been added to the SMP list pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The disclosure was made in compliance with SEBI Listing Regulations and Part A of Schedule III thereto, read with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Pratham Rawal, Company Secretary and Compliance Officer, signed the filing on July 29, 2026.

Appointee Details

The designations reflect the company’s focus on strengthening its technology and regulatory oversight capabilities. Both individuals are existing employees with significant tenure at Jagsonpal Pharmaceuticals Ltd.

Balmukund Keshav brings over 29 years of experience in IT leadership. During his 17-year tenure with Jagsonpal Pharmaceuticals Ltd, he has led digital transformation, ERP implementation, ITGC audits, and enterprise infrastructure management. His expertise covers IT governance, risk, information security, vendor management, and digital process automation.

Sanjay Singhal is a pharmacy professional with a master’s degree from Birla Institute of Technology, Pilani. He possesses 31 years of experience across manufacturing, supply chain, quality, and regulatory affairs. Singhal is also a government-approved technical person for all dosage forms across manufacturing and analytical divisions.

What This Means

The designation of these two executives as SMP formalizes their role in the company’s key decision-making and compliance framework. Under SEBI regulations, Senior Management Personnel are responsible for ensuring compliance with listing obligations and facilitating communication between the board and regulators. The move aligns with standard corporate governance practices following internal structural changes.

No financial impact or remuneration changes were disclosed in the filing. The appointments are administrative in nature, aimed at updating the company’s compliance records to reflect current operational leadership.